PCN43 Cost-Effectiveness of Nivolumab for the Treatment of Advanced Esophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy: A United-States Payer Perspective
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.135
https://www.valueinhealthjournal.com/article/S1098-3015(21)00352-1/fulltext
Title :
PCN43 Cost-Effectiveness of Nivolumab for the Treatment of Advanced Esophageal Squamous Cell Carcinoma Refractory or Intolerant to Previous Chemotherapy: A United-States Payer Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00352-1&doi=10.1016/j.jval.2021.04.135
First page :
Section Title :
Open access? :
No
Section Order :
10714